|
DUBAI, UAE, Dec. 15, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume has released its latest Crypto Derivatives Analytics Report in collaboration with Block Scholes.
The analysis reviews market conditions surrounding the year's final Federal Open Market Committee meeting, where policymakers delivered a widely expected 25 basis point rate cut. Chair Jerome Powell's remarks kept the possibility of either a pause or another cut in January 2026 in play, contributing to a restrained response across crypto markets.
Key Highlights:
Perpetuals: Open interest is still far lower than the levels it plummeted from pre-October 10, and funding rates in leveraged contracts suggest retail traders are still unwilling to re-enter positions in perpetual swap contracts.
Options: Volatility smiles are bearish across the whole term structure for both BTC and ETH with volatility smiles pricing in close to a 5 percent premium for OTM puts over calls for both short-dated and long-dated BTC and ETH options. As such, those waiting for a so-called Santa rally may end up disappointed, at least based on current positioning in derivatives markets.
The report highlights minimal shifts in perpetual swap activity, subdued implied volatility and continued skepticism in options positioning. While the Fed conveyed an improved economic outlook, sentiment in crypto derivatives remains cautious. BTC's spot price is still 28 percent below its all-time high, and options markets continue to price meaningful downside protection. According to the findings, traders have yet to see catalysts strong enough to support a late year resurgence.
Han Tan, Chief Market Analyst at Bybit Learn, said the broader macro backdrop continues to influence crypto market reactions. "The Fed's policy outlook will frame market reactions to this week's US jobs report and inflation data releases. Crypto bulls still have their work cut out to get any upside momentum going, considering that digital assets could only muster a tepid response to the final FOMC meeting of 2025, in stark contrast to global equities that surged to new record highs. Merely middling activity across the derivatives complex suggests that the window for a crypto 'santa rally' is getting narrower and the bar notably set higher."
The report concludes that traders are showing limited appetite to re-engage with leverage while options markets continue to indicate caution across short and long horizons. Current positioning suggests a tempered outlook for any year end rebound.
For detailed insights, readers may download the full report.
#Bybit / #TheCryptoArk / #BybitLearn
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit's Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
DUBAI, UAE, Dec. 15, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume has released its latest Crypto Derivatives Analytics Report in collaboration with Block Scholes.
The analysis reviews market conditions surrounding the year's final Federal Open Market Committee meeting, where policymakers delivered a widely expected 25 basis point rate cut. Chair Jerome Powell's remarks kept the possibility of either a pause or another cut in January 2026 in play, contributing to a restrained response across crypto markets.
Key Highlights:
Perpetuals: Open interest is still far lower than the levels it plummeted from pre-October 10, and funding rates in leveraged contracts suggest retail traders are still unwilling to re-enter positions in perpetual swap contracts.
Options: Volatility smiles are bearish across the whole term structure for both BTC and ETH with volatility smiles pricing in close to a 5 percent premium for OTM puts over calls for both short-dated and long-dated BTC and ETH options. As such, those waiting for a so-called Santa rally may end up disappointed, at least based on current positioning in derivatives markets.
The report highlights minimal shifts in perpetual swap activity, subdued implied volatility and continued skepticism in options positioning. While the Fed conveyed an improved economic outlook, sentiment in crypto derivatives remains cautious. BTC's spot price is still 28 percent below its all-time high, and options markets continue to price meaningful downside protection. According to the findings, traders have yet to see catalysts strong enough to support a late year resurgence.
Han Tan, Chief Market Analyst at Bybit Learn, said the broader macro backdrop continues to influence crypto market reactions. "The Fed's policy outlook will frame market reactions to this week's US jobs report and inflation data releases. Crypto bulls still have their work cut out to get any upside momentum going, considering that digital assets could only muster a tepid response to the final FOMC meeting of 2025, in stark contrast to global equities that surged to new record highs. Merely middling activity across the derivatives complex suggests that the window for a crypto 'santa rally' is getting narrower and the bar notably set higher."
The report concludes that traders are showing limited appetite to re-engage with leverage while options markets continue to indicate caution across short and long horizons. Current positioning suggests a tempered outlook for any year end rebound.
For detailed insights, readers may download the full report.
#Bybit / #TheCryptoArk / #BybitLearn
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit's Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Bybit and Block Scholes Report Finds Fed Outlook Fails to Lift Crypto Derivatives Sentiment
SINGAPORE, Dec. 15, 2025 /PRNewswire/ -- Curie Oncology, one of Southeast Asia's fastest-growing private oncology networks, has partnered with Singapore-based health-tech company Oncoshot to deploy AI-powered clinical research tools that help patients gain faster access to clinical trials.
The partnership marks one of the first real-world implementations of oncology-focused AI within a regional private cancer group, complementing earlier deployments across Singapore's public healthcare system.
Curie Oncology: using AI to bring more trials to patients
Curie Oncology currently runs numerous clinical trials across Singapore and Malaysia. As the group expands its research footprint, the volume of data required to identify eligible patients has increased significantly.
Digitalisation in healthcare has generated large volumes of data with valuable clinical insights. This information ranges from structured datasets like lab results to unstructured content such as free-text notes created inside and outside clinical environments. Yet over 80% of health data is unstructured, making it difficult for research teams to process efficiently or consistently. These limitations create significant barriers for researchers who need reliable, analysis-ready information.
Through the partnership, Curie Oncology is now using Oncoshot's AI tools to rapidly structure and analyse clinical data, enabling its oncologists and research teams to identify eligible patients sooner and offer access to ongoing trials more efficiently.
"Oncoshot helped us restructure our rich clinical and genomic data. We can now use natural language to query this information, enabling us to match patients to innovative therapies, improve patient outcomes, and perform cost-benefit analysis," said Dr Toh Chee Keong, medical oncologist and head of research at Curie Oncology.
AI as an enabler: Oncoshot's role in supporting Curie's research teams
Oncoshot's platform functions as a secure, behind-the-scenes engine that converts unstructured oncology documents into research-ready datasets. During Curie Oncology's rollout, the AI system:
- Extracted and de-identified data with over 95% accuracy, even across varied source systems
- Allowed research coordinators to spend more time on patient-facing and trial-critical tasks, instead of repetitive data processing
Oncoshot's role is to support, not replace, Curie's clinical research processes. The AI system helps teams screen faster, run feasibility checks more consistently, and scale their research programmes without requiring proportional increases in manpower.
"Our focus is to enable clinicians and research staff to do what they do best: care for patients and run high-quality clinical studies," said Dr Huren Sivaraj, CEO and head of clinical AI at Oncoshot. "AI simply removes the manual bottlenecks that make oncology research and access to innovative trials so resource intensive."
Public and private sector adoption
Curie Oncology is among the first private oncology networks in Asia to deploy Oncoshot's AI platform, extending the company's work with earlier public-facing collaborations across Singapore's cancer research ecosystem.
This includes earlier collaborations such as the 2022 project with Icon Cancer Centre and Roche to digitise genomic data, a workflow that has since been fully automated, as well as deployments with Tan Tock Seng Hospital and the National Cancer Centre Singapore which were highlighted in presentations at the International Association of Cancer Registries (IACR) 2025.
Together, these implementations illustrate how AI can support both public and private cancer institutions in processing unstructured oncology data securely and efficiently. Oncoshot's federated architecture ensures that raw patient data remains within each institution's environment, while maintaining compliance with HIPAA, GDPR, and Singapore PDPC regulations.
About Curie Oncology
Curie Oncology is a multi-site regional oncology group operating across Singapore, Malaysia, and the Philippines, with active collaborations in Indonesia and Vietnam. With a strong emphasis on clinical research, Curie runs numerous ongoing studies, providing patients with access to new therapies and precision oncology approaches.
About Oncoshot
Oncoshot is an oncology-focused AI company that helps hospitals and cancer centres transform unstructured clinical data into secure, analysis-ready datasets. Its in-premise medical LLM and federated architecture reduce friction in data extraction and standardisation, giving clinical and research teams faster access to the information needed for feasibility assessment, study planning, and real-world evidence generation.
By strengthening the data foundations that underpin oncology research, Oncoshot enables partners to accelerate cancer R&D and improve patient access to innovative treatments.
Visit www.oncoshot.com for more information.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Curie Oncology and Oncoshot Deploy AI to Improve Patient Outcomes in Asia
